FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Ola Weiland

Research Profile

Living Beings

Hepacivirus

Disorders

Chemicals & Drugs

Geographic Areas

Sweden

Procedures

Co-author Network

Publications

TOP 3
Magnus Lindh; S Nilsson; B Arnholm; Per Björkman; Kristoffer Hellstrand; Martin Lagging; T Wahlberg; E Wallmark; Ola Weiland; Rune Wejstål; Johan Westin; Anders Widell; Gunnar Norkrans
Dynamic tailoring of treatment durations improves efficiency of hepatitis C treatment with pegylated interferon and ribavirin.
J Stenkvist; A Sönnerborg; Ola Weiland
HCV RNA decline in chronic HCV genotype 2 and 3 during standard of care treatment according to IL28B polymorphism.
Martin Lagging; Magnus Lindh; Ola Weiland; Rune Wejstål; Soo Aleman; Ann-Sofi Duberg; Filip Josephson
Treatment of hepatitis C virus infection in adults and children: updated Swedish consensus recommendations.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Ola Weiland (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Magnus Lindh; S Nilsson; B Arnholm; Per Björkman; Kristoffer Hellstrand; Martin Lagging; T Wahlberg; E Wallmark; Ola Weiland; Rune Wejstål; Johan Westin; Anders Widell; Gunnar Norkrans
Dynamic tailoring of treatment durations improves efficiency of hepatitis C treatment with pegylated interferon and ribavirin.
Journal of viral hepatitis 2013;20(4):e82-9.
2013: J Stenkvist; A Sönnerborg; Ola Weiland
HCV RNA decline in chronic HCV genotype 2 and 3 during standard of care treatment according to IL28B polymorphism.
Journal of viral hepatitis 2013;20(3):193-9.
2012: Martin Lagging; Magnus Lindh; Ola Weiland; Rune Wejstål; Soo Aleman; Ann-Sofi Duberg; Filip Josephson
Treatment of hepatitis C virus infection in adults and children: updated Swedish consensus recommendations.
Scandinavian journal of infectious diseases 2012;44(7):502-21.
2010: Jenny Nilsson; Ola Weiland
Effect of control selection on sustained viral response rates in genotype 2/3 HCV mono-infected versus HIV/HCV co-infected patients.
Scandinavian journal of infectious diseases 2010;42(6-7):533-9.
2009: Ann Wejdmark; Ola Weiland
[Measurement of liver elasticity can differentiate high and low grade fibrosis. New method can reduce the need of liver biopsy in chronic hepatitis C].
Läkartidningen 2009;106(50-51):3420-3.
2009: Per Stål; Erik von Seth; Annika Bergquist; Antal Nemeth; Ola Weiland
[Elastography--a new tool for diagnosis of chronic liver diseases. Might replace liver biopsy, but not always].
Läkartidningen 2009;106(50-51):3412-4, 3416, 3418.
2009: Veronica D Gonzalez; Karolin Falconer; Niklas K Björkström; Kim G Blom; Ola Weiland; Hans-Gustaf Ljunggren; Annette Alaeus; Johan K Sandberg
Expansion of functionally skewed CD56-negative NK cells in chronic hepatitis C virus infection: correlation with outcome of pegylated IFN-alpha and ribavirin treatment.
Journal of immunology (Baltimore, Md. : 1950) 2009;183(10):6612-8.
2009: Martin Lagging; Rune Wejstål; Ingrid Uhnoo; Barbro Gerdén; Björn Fischler; Styrbjörn Friman; Filip Josephson; Olle Karlström; Per Sangfelt; Robert Schvarz; Ola Weiland
Treatment of hepatitis C virus infection: updated Swedish Consensus recommendations.
Scandinavian journal of infectious diseases 2009;41(6-7):389-402.
2008: Niklas K Björkström; Veronica D Gonzalez; Karl-Johan Malmberg; Karolin Falconer; Annette Alaeus; Greg Nowak; Carl Jorns; Bo-Göran Ericzon; Ola Weiland; Johan K Sandberg; Hans-Gustaf Ljunggren
Elevated numbers of Fc gamma RIIIA+ (CD16+) effector CD8 T cells with NK cell-like function in chronic hepatitis C virus infection.
Journal of immunology (Baltimore, Md. : 1950) 2008;181(6):4219-28.
2008: Ola Weiland; Anna Hollander; L Mattsson; H Glaumann; Karin Lindahl; Robert Schvarcz; Gudrun Lindh; R Enquist; A Quist
Lower-than-standard dose peg-IFN alfa-2a for chronic hepatitis C caused by genotype 2 and 3 is sufficient when given in combination with weight-based ribavirin.
Journal of viral hepatitis 2008;15(9):641-5.
2008: Ola Weiland
[Immunoglobulin or vaccine as post-exposure prophylaxis against hepatitis A. The vaccine is sufficient for many according to the first controlled study].
Läkartidningen 2008;105(19):1371-2.
2008: Tony Carlsson; Anne Quist; Ola Weiland
Rapid viral response and treatment outcome in genotype 2 and 3 chronic hepatitis C: comparison between two HCV RNA quantitation methods.
Journal of medical virology 2008;80(5):803-7.
2008: Eliya Syed; Nogol Rahbin; Ola Weiland; Tony Carlsson; Antti Oksanen; M Birk; Loa Davidsdottir; Karin Hagen; Rolf Hultcrantz; Soo Aleman
Pegylated interferon and ribavirin combination therapy for chronic hepatitis C virus infection in patients with Child-Pugh Class A liver cirrhosis.
Scandinavian journal of gastroenterology 2008;43(11):1378-86.
2008: Magnus Lindh; Ingrid Uhnoo; Joans Bläckberg; Ann-Sofi Duberg; Stybjörn Friman; Björn Fischler; Olof Karlström; Gunnar Norkrans; Olle Reichard; Per Sangfeldt; Ann Söderström; Anders Sönnerborg; Ola Weiland; Rune Wejstål; Johan Wiström
Treatment of chronic hepatitis B infection: an update of Swedish recommendations.
Scandinavian journal of infectious diseases 2008;40(6-7):436-50.
2008: Per Sangfelt; Ingrid Uhnoo; Olle Reichard; Ola Weiland
A low-dose intradermal hepatitis B vaccine programme in health-care workers and students is highly effective and cost saving: a retrospective follow-up survey in the clinical setting.
Scandinavian journal of gastroenterology 2008;43(4):465-72.
2008: Erika Hörnfeldt; Henrik Gjertsen; Ola Weiland
High adherence with a low initial ribavirin dose in combination with pegylated-IFN alpha-2a for treatment of recurrent hepatitis C after liver transplantation.
Scandinavian journal of infectious diseases 2008;40(3):259-65.
2007: Mathias Lidgren; Anna Hollander; Ola Weiland; Bengt Jönsson
Productivity improvements in hepatitis C treatment: impact on efficacy, cost, cost-effectiveness and quality of life.
Scandinavian journal of gastroenterology 2007;42(7):867-77.
2007: Isabelle Desombere; Hans Van Vlierberghe; Ola Weiland; Catharina Hultgren; Matti Sällberg; Juan Quiroga; Vicente Carreño; Geert Leroux-Roels
Serum levels of anti-NS4a and anti-NS5a predict treatment response of patients with chronic hepatitis C.
Journal of medical virology 2007;79(6):701-13.
2007: Graham R Foster; Michael W Fried; Stephanos J Hadziyannis; Diethelm Messinger; Klaus Freivogel; Ola Weiland
Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin.
Scandinavian journal of gastroenterology 2007;42(2):247-55.
2006: Anna Hollander; Graham R Foster; Ola Weiland
Health-related quality of life before, during and after combination therapy with interferon and ribavirin in unselected Swedish patients with chronic hepatitis C.
Scandinavian journal of gastroenterology 2006;41(5):577-85.
2006: Jonas Söderholm; Gustaf Ahlén; A Kaul; Lars Frelin; Mats Alheim; Christina Barnfield; Peter Liljeström; Ola Weiland; David R Milich; R Bartenschlager; Matti Sällberg
Relation between viral fitness and immune escape within the hepatitis C virus protease.
Gut 2006;55(2):266-74.
2006: Björn Olsen; Diana Axelsson-Olsson; Anders Thelin; Ola Weiland
Unexpected high prevalence of IgG-antibodies to hepatitis E virus in Swedish pig farmers and controls.
Scandinavian journal of infectious diseases 2006;38(1):55-8.
2005: Tony Carlsson; Olle Reichard; Gunnar Norkrans; J Bläckberg; Per Sangfelt; E Wallmark; Ola Weiland
Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response.
Journal of viral hepatitis 2005;12(5):473-80.
2004: Bart J Veldt; G Saracco; N Boyer; Calogero Cammà; A Bellobuono; U Hopf; I Castillo; Ola Weiland; Frederik Nevens; Bettina E Hansen; Solko W Schalm
Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy.
Gut 2004;53(10):1504-8.
2004: Catharina Hultgren; Isabelle Desombere; Geert Leroux-Roels; Juan A Quiroga; Vincente Carreno; Bo Nilsson; Ola Weiland; Matti Sällberg
Evidence for a relation between the viral load and genotype and hepatitis C virus-specific T cell responses.
Journal of hepatology 2004;40(6):971-8.
2004: Lars Frelin; Gustaf Ahlén; Mats Alheim; Ola Weiland; Christina Barnfield; Peter Liljeström; Matti Sällberg
Codon optimization and mRNA amplification effectively enhances the immunogenicity of the hepatitis C virus nonstructural 3/4A gene.
Gene therapy 2004;11(6):522-33.
2004: Anna Hollander; Hans Glaumann; Ola Weiland
Histological findings, genotype distribution and percentage of patients fulfilling the treatment criteria among patients with chronic hepatitis C virus infection in a single Swedish centre.
Scandinavian journal of gastroenterology 2004;39(2):164-7.
2004: Per Sangfelt; Madeleine Von Sydow; Ingrid Uhnoo; Ola Weiland; Gudrun Lindh; Björn Fischler; Susanne Lindgren; Olle Reichard
Serum ALT levels as a surrogate marker for serum HBV DNA levels in HBeAg-negative pregnant women.
Scandinavian journal of infectious diseases 2004;36(3):182-5.
2003: Rune Wejstål; Annette Alaeus; Björn Fischler; Olle Reichard; Ingrid Uhnoo; Ola Weiland
Chronic hepatitis C: updated Swedish consensus.
Scandinavian journal of infectious diseases 2003;35(8):445-51.
2003: Ligita Balciuniene; Tony Carlsson; Arvydas Ambrozaitis; Olle Reichard; Ola Weiland
Hepatitis C virus RNA levels during initial induction or standard interferon therapy: influence of continued treatment on sustained response.
Scandinavian journal of infectious diseases 2003;35(3):180-5.
2002: Tony Carlsson; Ola Weiland; Olle Reichard
Viral kinetics and treatment response in patients with hepatitis C during induction and standard interferon therapy in combination with ribavirin.
Scandinavian journal of gastroenterology 2002;37(10):1228-34.
2002: Miguel A Rico; Juan A Quiroga; Dolores Subirá; Esteban Garcia; Susana Castañón; Matti Sällberg; Geert Leroux-Roels; Ola Weiland; Margarita Pardo; Vicente Carreño
Features of the CD4+ T-cell response in liver and peripheral blood of hepatitis C virus-infected patients with persistently normal and abnormal alanine aminotransferase levels.
Journal of hepatology 2002;36(3):408-16.
2002: Per Sangfelt; Ingrid Uhnoo; Anna Hollander; Gudrun Lindh; Ola Weiland
Lamivudine and famciclovir combination therapy with or without addition of interferon-alpha-2b for HBeAg-positive chronic hepatitis B: a pilot study.
Scandinavian journal of infectious diseases 2002;34(7):505-11.
2001: Una Lazdina; Catharina Hultgren; Lars Frelin; M Chen; K Lodin; Ola Weiland; Geert Leroux-Roels; Juan A Quiroga; Darrell L Peterson; David R Milich; Matti Sällberg
Humoral and CD4(+) T helper (Th) cell responses to the hepatitis C virus non-structural 3 (NS3) protein: NS3 primes Th1-like responses more effectively as a DNA-based immunogen than as a recombinant protein.
The Journal of general virology 2001;82(Pt 6):1299-308.
2001: Tony Carlsson; Olle Reichard; Ola Weiland
Hepatitis C virus kinetics during induction and standard 3 times a week interferon-alpha therapy.
Scandinavian journal of infectious diseases 2001;33(11):838-42.
2001: R Halasz; Ola Weiland; Matti Sällberg
GB virus C/hepatitis G virus.
Scandinavian journal of infectious diseases 2001;33(8):572-80.
2000: R Halasz; Matti Sällberg; S Lundholm; G Andersson; B Lager; Hans Glaumann; Ola Weiland
The GB virus C/hepatitis G virus replicates in hepatocytes without causing liver disease in healthy blood donors.
The Journal of infectious diseases 2000;182(6):1756-60.
2000: Una Lazdina; Catharina Hultgren; M Chen; Björn Fischler; Ola Weiland; I K Mushahwar; Matti Sällberg
Humoral and cellular immune responses to the GB virus C/hepatitis G virus envelope 2 protein.
Journal of medical virology 2000;62(3):334-44.
2000: Rune Wejstål; Björn Fischler; Hans Glaumann; Gunnar Norkrans; Olle Reichard; A Sönnerbor; Ingrid Uhnoo; Ola Weiland
Chronic hepatitis C--Swedish experts' meeting recommends combination treatment.
Scandinavian journal of infectious diseases 2000;32(5):465-70.
1999: Catharina Hultgren; Ola Weiland; David R Milich; Matti Sällberg
Cell-mediated immune responses and loss of hepatitis B e-antigen (HBeAg) during successful lamivudine and famciclovir combination therapy for chronic replicating hepatitis B virus infection.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1999;29(6):1575-7.
1999: Rune Wejstål; Björn Fischler; Hans Glaumann; Gunnar Norkrans; Olle Reichard; Anders Sönnerborg; Ingrid Uhnoo; Ola Weiland
[Recommendations from a Swedish meeting of experts. Hepatitis C is to be treated with the combination of interferon and ribavirin].
Läkartidningen 1999;96(44):4795-8, 4800.
1999: Solko W Schalm; Ola Weiland; B E Hansen; M Milella; M Y Lai; Anna Hollander; Peter P Michielsen; A Bellobuono; Liliana Chemello; G Pastore; D S Chen; Johannes T Brouwer
Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis.
Gastroenterology 1999;117(2):408-13.
1999: Robert Schvarcz; Hans Glaumann; Olle Reichard; Ola Weiland
Histological and virological long-term outcome in patients treated with interferon-alpha2b and ribavirin for chronic hepatitis C.
Journal of viral hepatitis 1999;6(3):237-42.
1999: Olle Reichard; Hans Glaumann; Aril Frydén; Gunnar Norkrans; Rune Wejstål; Ola Weiland
Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon.
Journal of hepatology 1999;30(5):783-7.
1999: Ola Weiland
Treatment of naive patients with chronic hepatitis C.
Journal of hepatology 1999;31 Suppl 1():168-73.
1999: Ola Weiland; Jean Henrik Braconier; Aril Frydén; Gunnar Norkrans; Olle Reichard; Ingrid Uhnoo
Influence of pre-treatment factors on outcome of interferon-alpha treatment of patients with chronic hepatitis C.
Scandinavian journal of infectious diseases 1999;31(2):115-8.
1999: Tony Carlsson; Johan Struwe; Anders Sönnerborg; Ola Weiland
The anti-HBs response after 2 different accelerated intradermal and intramuscular schemes for hepatitis B vaccination.
Scandinavian journal of infectious diseases 1999;31(1):93-5.
1999: M Chen; Matti Sällberg; Anders Sönnerborg; Ola Weiland; L Mattsson; L Jin; AJ Birkett; D Peterson; David R Milich
Limited humoral immunity in hepatitis C virus infection.
Gastroenterology 1999;116(1):135-43.
1998: Catharina Hultgren; David R Milich; Ola Weiland; Matti Sällberg
The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses.
The Journal of general virology 1998;79 ( Pt 10)():2381-91.
1998: Jacob Odeberg; Z Yun; Anders Sönnerborg; Ola Weiland; Joakim Lundeberg
Variation in the hepatitis C virus NS5a region in relation to hypervariable region 1 heterogeneity during interferon treatment.
Journal of medical virology 1998;56(1):33-8.
1998: Ola Weiland
Can HCV infection be cleared?
Lancet 1998;352(9129):669-70.
1998: M Chen; Matti Sällberg; Anders Sönnerborg; L Jin; AJ Birkett; D Peterson; Ola Weiland; David R Milich
Human and murine antibody recognition is focused on the ATPase/helicase, but not the protease domain of the hepatitis C virus nonstructural 3 protein.
Hepatology (Baltimore, Md.) 1998;28(1):219-24.
1998: Steven Shev; Per Björkman; Gunnar Norkrans; U Foberg; Aril Frydén; Gudrun Lindh; A Lindholm; Ola Weiland; Anders Widell
GBV-C/HGV infection in hepatitis C virus-infected deferred Swedish blood donors.
Journal of medical virology 1998;54(2):75-9.
1998: Olle Reichard; Gunnar Norkrans; Aril Frydén; Jean Henrik Braconier; Anders Sönnerborg; Ola Weiland
Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group.
Lancet 1998;351(9096):83-7.
1998: Olle Reichard; Gunnar Norkrans; Aril Frydén; Jean Henrik Braconier; Anders Sönnerborg; Ola Weiland
Comparison of 3 quantitative HCV RNA assays--accuracy of baseline viral load to predict treatment outcome in chronic hepatitis C.
Scandinavian journal of infectious diseases 1998;30(5):441-6.
1997: Olle Reichard; Robert Schvarcz; Ola Weiland
Therapy of hepatitis C: alpha interferon and ribavirin.
Hepatology (Baltimore, Md.) 1997;26(3 Suppl 1):108S-111S.
1997: Z X Zhang; David R Milich; Darrell L Peterson; AJ Birkett; Robert Schvarcz; Ola Weiland; Matti Sällberg
Interferon-alpha treatment induces delayed CD4 proliferative responses to the hepatitis C virus nonstructural protein 3 regardless of the outcome of therapy.
The Journal of infectious diseases 1997;175(6):1294-301.
1997: Z Yun; B Johansson; Ola Weiland; Anders Sönnerborg
Genotyping of hepatitis C virus performed by type-specific PCR in comparison to nucleotide sequencing of NS5 and core regions.
Research in virology 1997;148(3):233-7.
1997: Solko W Schalm; Bettina E Hansen; Liliana Chemello; A Bellobuono; Johannes T Brouwer; Ola Weiland; Luisa Cavalletto; Robert Schvarcz; G Ideo; Alfredo Alberti
Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers.
Journal of hepatology 1997;26(5):961-6.
1996: Geoffrey Dusheiko; J Main; Howard Thomas; Olle Reichard; C Lee; A Dhillon; S Rassam; A Fryden; H Reesink; M Bassendine; Gunnar Norkrans; T Cuypers; N Lelie; P Telfer; J Watson; C Weegink; P Sillikens; Ola Weiland
Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study.
Journal of hepatology 1996;25(5):591-8.
1996: Johan Struwe; Johan Giesecke; Gudrun Lindh; Ola Weiland
Utility of an anonymous questionnaire for the identification of a primary transmission route and possible secondary transmission in adults with acute hepatitis B virus infection.
European journal of epidemiology 1996;12(3):319-22.
1996: Johan Struwe; B Aronsson; M Forsgren; B Frenning; M von Sydow; Ola Weiland
[Hepatitis B is an occupational risk for health personnel. Preventive vaccination is recommended].
Läkartidningen 1996;93(10):884-8.
1995: Johan Struwe; O Norrbohm; J Stenbeck; Johan Giesecke; Ola Weiland
Risk factors for hepatitis A, B and C virus infection among Swedish expatriates.
The Journal of infection 1995;31(3):205-9.
1995: S Shev; Anders Widell; U Foberg; Aril Frydén; Svante Hermodsson; Gudrun Lindh; A Lindholm; S Månsson; Ola Weiland; Gunnar Norkrans
HCV genotypes in Swedish blood donors as correlated to epidemiology, liver disease and hepatitis C virus antibody profile.
Infection 1995;23(5):253-7.
1995: Robert Schvarcz; Z Yun; Anders Sönnerborg; Ola Weiland
Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone.
Journal of medical virology 1995;46(1):43-7.
1995: Olle Reichard; Hans Glaumann; Aril Frydén; Gunnar Norkrans; Robert Schvarcz; Anders Sönnerborg; Z Yun; Ola Weiland
Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment.
Hepatology (Baltimore, Md.) 1995;21(4):918-22.
1995: Robert Schvarcz; Y Ando; Anders Sönnerborg; Ola Weiland
Combination treatment with interferon alfa-2b and ribavirin for chronic hepatitis C in patients who have failed to achieve sustained response to interferon alone: Swedish experience.
Journal of hepatology 1995;23 Suppl 2():17-21.
1995: Ola Weiland; M Chen; Gudrun Lindh; L Mattsson; Robert Schvarcz; Anders Sönnerborg; M Wahl; Rune Wejstål; Anders Widell; Gunnar Norkrans
Efficacy of human leucocyte alpha-interferon treatment for chronic hepatitis C virus infection.
Scandinavian journal of infectious diseases 1995;27(4):319-24.
1995: Ola Weiland; M Chen; Gudrun Lindh; L Mattsson; Robert Schvarcz; Anders Sönnerborg; M Wahl; Rune Wejstål; Anders Widell; Gunnar Norkrans
Efficacy of human leucocyte alpha-interferon treatment for chronic hepatitis C virus infection.
Scandinavian journal of infectious diseases 1995;27(5):319-24.
1995: Johan Struwe; B Aronsson; B Frenning; M Forsgren; Ola Weiland
Response to a booster dose 18 months after a low anti-HBs response (10-99 IU/l) to three doses of intradermally or intramuscularly administered recombinant hepatitis B vaccine.
Infection 1995;23(1):42-5.
1994: Anders Widell; S Shev; S Månsson; Y Y Zhang; U Foberg; Gunnar Norkrans; Aril Frydén; Ola Weiland; J Kurkus; E Nordenfelt
Genotyping of hepatitis C virus isolates by a modified polymerase chain reaction assay using type specific primers: epidemiological applications.
Journal of medical virology 1994;44(3):272-9.
1994: Robert Schvarcz; B G Hansson; J O Lernestedt; Ola Weiland
Treatment of chronic replicative hepatitis B virus infection with short-term continuous infusion of foscarnet.
Infection 1994;22(5):330-2.
1994: Olle Reichard; Hans Glaumann; Gunnar Norkrans; Rune Wejstål; A Fryden; Robert Schvarcz; Ola Weiland
Histological outcome in patients with chronic hepatitis C given a 60-week interferon alfa-2b treatment course.
Liver 1994;14(4):169-74.
1994: Z Yun; Joakim Lundeberg; B Johansson; A Hedrum; Ola Weiland; Mathias Uhlén; Anders Sönnerborg
Colorimetric detection of competitive PCR products for quantification of hepatitis C viremia.
Journal of virological methods 1994;47(1-2):1-13.
1994: Johan Struwe; B Aronsson; B Frenning; M Forsgren; Ola Weiland
Prevalence of antibodies against hepatitis C virus infection among health care workers in Stockholm.
Scandinavian journal of gastroenterology 1994;29(4):360-2.
1994: Olle Reichard; U Foberg; Aril Frydén; L Mattsson; Gunnar Norkrans; Anders Sönnerborg; Rune Wejstål; Z Yun; Ola Weiland
High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-alpha 2b for 60 weeks.
Hepatology (Baltimore, Md.) 1994;19(2):280-5.
1994: Johan Struwe; B Aronsson; B Frenning; M Forsgren; Ola Weiland
Seroconversion after additional vaccine doses to non-responders to three doses of intradermally or intramuscularly administered recombinant hepatitis B vaccine.
Scandinavian journal of infectious diseases 1994;26(4):468-70.
1994: Olle Reichard; Hans Glaumann; Ola Weiland
Long-term histological outcome in patients with chronic hepatitis C treated repeatedly with interferon alpha-2b without sustained response.
Scandinavian journal of infectious diseases 1994;26(4):383-9.
1994: Z Yun; Olle Reichard; M Chen; Joakim Lundeberg; Gunnar Norkrans; A Fryden; Anders Sönnerborg; Ola Weiland
Serum hepatitis C virus RNA levels in chronic hepatitis C--importance for outcome of interferon alfa-2b treatment.
Scandinavian journal of infectious diseases 1994;26(3):263-70.
1993: Olle Reichard; Z Yun; Anders Sönnerborg; Ola Weiland
Hepatitis C viral RNA titers in serum prior to, during, and after oral treatment with ribavirin for chronic hepatitis C.
Journal of medical virology 1993;41(2):99-102.
1993: L Mattsson; Anders Sönnerborg; Ola Weiland
Outcome of acute symptomatic non-A, non-B hepatitis: a 13-year follow-up study of hepatitis C virus markers.
Liver 1993;13(5):274-8.
1993: Robert Schvarcz; Hans Glaumann; Ola Weiland
Survival and histological resolution of fibrosis in patients with autoimmune chronic active hepatitis.
Journal of hepatology 1993;18(1):15-23.
1993: Johan Struwe; K Käll; P Stendahl; G Scalia-Tomba; Johan Giesecke; Ola Weiland
Prevalence of hepatitis B virus markers among intravenous drug abusers in Stockholm: impact of heterosexual transmission.
Scandinavian journal of infectious diseases 1993;25(1):8-13.
1993: Christer Lidman; Lars O Magnius; Helene Norder; Ola Weiland
Interferon alpha-2b treatment in an HIV-infected patient with hepatitis B virus induced nephrotic syndrome.
Scandinavian journal of infectious diseases 1993;25(1):133-5.
1993: Ola Weiland; Y Y Zhang; Anders Widell
Serum HCV RNA levels in patients with chronic hepatitis C given a second course of interferon alpha-2b treatment after relapse following initial treatment.
Scandinavian journal of infectious diseases 1993;25(1):25-30.
1993: S Shev; U Foberg; A Fryden; Svante Hermodsson; Gudrun Lindh; A Lindholm; A S Månsson; M von Sydow; Ola Weiland; Anders Widell
Second-generation hepatitis C Elisa antibody tests confirmed by the four-antigen recombinant immunoblot assay correlate well with hepatitis C viremia and chronic liver disease in Swedish blood donors.
Vox sanguinis 1993;65(1):32-7.
1993: Z Yun; G Lindh; Ola Weiland; B Johansson; Anders Sönnerborg
Detection of hepatitis C virus (HCV) RNA by PCR related to HCV antibodies in serum and liver histology in Swedish blood donors.
Journal of medical virology 1993;39(1):57-61.
1992: Rune Wejstål; Gunnar Norkrans; R Lenkei; Ola Weiland; Robert Schvarcz; Aril Frydén
Peripheral blood lymphocyte subsets in patients with chronic hepatitis C--effects of interferon treatment.
Liver 1992;12(4 Pt 1):161-7.
1992: D Fuchs; Gunnar Norkrans; R Wejstal; G Reibnegger; Günter Weiss; Ola Weiland; Robert Schvarcz; A Fryden; H Wachter
Changes of serum neopterin, beta 2-microglobulin and interferon-gamma in patients with chronic hepatitis C treated with interferon-alpha 2b.
The European journal of medicine 1992;1(4):196-200.
1992: J Mårtensson; U Foberg; A Fryden; Morton K Schwartz; B Sörbo; Ola Weiland
Sulfur amino acid metabolism in hepatobiliary disorders.
Scandinavian journal of gastroenterology 1992;27(5):405-11.
1992: Ola Weiland; Robert Schvarcz
Hepatitis C: virology, epidemiology, clinical course, and treatment.
Scandinavian journal of gastroenterology 1992;27(5):337-42.
1992: G G Schlauder; G J Leverenz; L Mattsson; Ola Weiland; Isa K Mushahwar
Detection of hepatitis C viral RNA by the polymerase chain reaction in serum of patients with post-transfusion non-A, non-B hepatitis.
Journal of virological methods 1992;37(2):189-99.
1992: Johan Struwe; B Aronsson; B Frenning; M Forsgren; Ola Weiland
Prevalence of hepatitis B virus markers and exposure to occupational risks likely to be associated with acquisition of hepatitis B virus among health care workers in Stockholm.
The Journal of infection 1992;24(2):147-56.
1992: Rune Wejstål; Gunnar Norkrans; Ola Weiland; Robert Schvarcz; D Fuchs; H Wachter; A Fryden; Hans Glaumann
Lymphocyte subsets and beta 2-microglobulin expression in chronic hepatitis C/non-A, non-B. Effects of interferon-alpha treatment.
Clinical and experimental immunology 1992;87(3):340-5.
1992: Johan Struwe; Johan Giesecke; P Olcen; M von Sydow; Ola Weiland
Prevalence of hepatitis B virus markers in Sweden: a community-based serosurvey of 4,000 young Swedish adults.
American journal of epidemiology 1992;135(4):409-17.
1992: Johan Struwe; B Aronsson; B Frenning; Fredrik Granath; M von Sydow; Ola Weiland
Intramuscular versus intradermal administration of a recombinant hepatitis B vaccine: a comparison of response rates and analysis of factors influencing the antibody response.
Scandinavian journal of infectious diseases 1992;24(4):423-9.
1992: L Mattsson; L Grillner; Ola Weiland
Seroconversion to hepatitis C virus antibodies in patients with acute posttransfusion non-A, non-B hepatitis in Sweden with a second generation test.
Scandinavian journal of infectious diseases 1992;24(1):15-20.
1991: L Mattsson; Robin A Gutierrez; George J Dawson; R R Lesniewski; L K Mushahwar; Ola Weiland
Antibodies to recombinant and synthetic peptides derived from the hepatitis C virus genome in long-term-studied patients with posttransfusion hepatitis C.
Scandinavian journal of gastroenterology 1991;26(12):1257-62.
1991: K H Chau; George J Dawson; Isa K Mushahwar; Robin A Gutierrez; R G Johnson; R R Lesniewski; L Mattsson; Ola Weiland
IgM-antibody response to hepatitis C virus antigens in acute and chronic post-transfusion non-A, non-B hepatitis.
Journal of virological methods 1991;35(3):343-52.
1991: L Mattsson; L Grillner; M von Sydow; S Bergdahl; Ola Weiland
Seroconversion to hepatitis C virus antibodies in patients with acute posttransfusion non-A, non-B hepatitis in Sweden.
Infection 1991;19(5):309-12.
1991: Olle Reichard; J Andersson; Robert Schvarcz; Ola Weiland
Ribavirin treatment for chronic hepatitis C.
Lancet 1991;337(8749):1058-61.
1991: Robert Schvarcz; Hans Glaumann; Ola Weiland; Gunnar Norkrans; Rune Wejstål; Aril Frydén
Histological outcome in interferon alpha-2b treated patients with chronic posttransfusion non-A, non-B hepatitis.
Liver 1991;11(1):30-8.
1991: Robert Schvarcz; Hans Glaumann; Ola Weiland; Gunnar Norkrans; Rune Wejstål; Aril Frydén
Interferon alpha-2b treatment of chronic posttransfusion non-A, non-B/C hepatitis: long-term outcome and effect of increased interferon doses in non-responders.
Scandinavian journal of infectious diseases 1991;23(4):413-20.
1991: L Mattsson; B Aberg; M von Sydow; Ola Weiland
Incidence of hepatitis and seroconversion to hepatitis C virus after open-heart surgery in transfused and non-transfused patients in Sweden.
Scandinavian journal of infectious diseases 1991;23(1):25-9.
1990: Robert Schvarcz; M von Sydow; Ola Weiland
Autoimmune chronic active hepatitis: changing reactivity for antibodies to hepatitis C virus after immunosuppressive treatment.
Scandinavian journal of gastroenterology 1990;25(11):1175-80.
1990: Gudrun Lindh; L Mattsson; M von Sydow; Ola Weiland
Acute hepatitis B and hepatitis D co-infection in the Stockholm region in the 1970s and 1980s--a comparison.
Infection 1990;18(6):357-60.
1990: L Mattsson; Ola Weiland; Hans Glaumann
Application of a numerical scoring system for assessment of histological outcome in patients with chronic posttransfusion non-A, non-B hepatitis with or without antibodies to hepatitis C.
Liver 1990;10(5):257-63.
1990: B Aronsson; B Frenning; Johan Struwe; Ola Weiland
[Preventive vaccination against hepatitis B of health care personnel is a good investment].
Läkartidningen 1990;87(36):2775-6.
1990: Ola Weiland; Gudrun Lindh; L Mattsson; Robert Schvarcz; M Von Sydow
[Hepatitis C virus a common cause of chronic hepatitis in Sweden].
Läkartidningen 1990;87(34):2567-8.
1990: Johan Struwe; Johan Giesecke; Gudrun Lindh; Ola Weiland
Heterosexual contact as a major route for transmission of acute hepatitis B among adults.
The Journal of infection 1990;20(2):111-21.
1990: Ola Weiland; Robert Schvarcz; Rune Wejstål; Gunnar Norkrans; Aril Frydén
Therapy of chronic post-transfusion non-A, non-B hepatitis with interferon alfa-2b: Swedish experience.
Journal of hepatology 1990;11 Suppl 1():S57-62.
1990: L Mattsson; U Lindqvist; Ola Weiland; B Aberg
Serum levels of the aminoterminal propeptide of type III procollagen and hyaluronan during resolving and nonresolving posttransfusion non-A, non-B hepatitis.
Scandinavian journal of infectious diseases 1990;22(1):11-7.
1989: L Mattsson; Ola Weiland; Hans Glaumann
Chronic non-A, non-B hepatitis developed after transfusions, illicit self-injections or sporadically. Outcome during long-term follow-up--a comparison.
Liver 1989;9(2):120-7.
1989: Ola Weiland; Robert Schvarcz; Rune Wejstål; Gunnar Norkrans; U Foberg; Aril Frydén
Interferon alpha-2b treatment of chronic posttransfusion non-A, non-B hepatitis: interim results of a randomized controlled open study.
Scandinavian journal of infectious diseases 1989;21(2):127-32.
1989: Robert Schvarcz; Ola Weiland; Rune Wejstål; Gunnar Norkrans; Aril Frydén; U Foberg
A randomized controlled open study of interferon alpha-2b treatment of chronic non-A, non-B posttransfusion hepatitis: no correlation of outcome to presence of hepatitis C virus antibodies.
Scandinavian journal of infectious diseases 1989;21(6):617-25.
1988: J Struve; Ola Weiland; C E Nord
Lactobacillus plantarum endocarditis in a patient with benign monoclonal gammopathy.
The Journal of infection 1988;17(2):127-30.
1988: L Mattsson; Ola Weiland; Hans Glaumann
Long-term follow-up of chronic post-transfusion non-A, non-B hepatitis: clinical and histological outcome.
Liver 1988;8(3):184-8.
1988: Gudrun Lindh; Ola Weiland; Hans Glaumann
The application of a numerical scoring system for evaluating the histological outcome in patients with chronic hepatitis B followed in long-term.
Hepatology (Baltimore, Md.) 1988;8(1):98-103.
1988: L Mattsson; B Aberg; Ola Weiland; M Sellman; J Davilén
Non-A, non-B hepatitis after open-heart surgery in Stockholm: declining incidence after introduction of restrictions for blood donations due to the human immunodeficiency virus.
Scandinavian journal of infectious diseases 1988;20(4):371-6.
1988: Robert Schvarcz; Ola Weiland; Hans Glaumann
Alpha interferon treatment of chronic non-A, non-B hepatitis caused by intravenous gammaglobulin.
Scandinavian journal of infectious diseases 1988;20(2):231-2.
1987: U Foberg; C Broström; Aril Frydén; H Glaumann; B Kågedal; J Mårtensson; P Tobiasson; Ola Weiland
Evaluation of an oral bile acid loading test for assessment of liver function in chronic hepatitis. A comparison with fasting serum bile acids and i.v. galactose elimination test.
Liver 1987;7(2):116-22.
1986: B G Hansson; Gudrun Lindh; Ola Weiland; Hans Glaumann; M von Sydow; E Nordenfeldt
Long-term follow-up of 60 patients with chronic hepatitis B. II. Hepatitis B virus DNA in serum correlated to the hepatitis Be-system and presence of delta superinfection.
Liver 1986;6(5):292-6.
1986: U Foberg; Aril Frydén; Erik Kihlström; K Persson; Ola Weiland
Yersinia enterocolitica septicemia: clinical and microbiological aspects.
Scandinavian journal of infectious diseases 1986;18(4):269-79.